my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Archimedes Pharma Ltd announced the decision by the Scottish Medicines Consortium (SMC) to accept PecFent® (fentanyl pectin nasal spray) for use within NHS Scotland. PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for ch more
Archimedes Pharma Ltd. announced that the European Commission has granted marketing authorisation for its lead product, PecFent, a fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakt more
Archimedes Pharma announced that it has raised £65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes more
This study aims to analyze the quality of reporting and its correlates in randomized controlled trials (RCTs) on acupuncture for cancer pain. Quality of reporting for included papers was assessed against a subset of criteria adapted from the CONSORT 2010 statement and STRICTA. An overall quality sco more
Ogboli-Nwasor EO, Makama JG, Yusufu LM more
Fentanyl pectin nasal spray is a novel intranasal formulation for the management of breakthrough cancer pain in patients taking and tolerant to opioids for persistent cancer pain. The pectin-based delivery modulates the product’s transmucosal absorption. Nasal delivery allows fentanyl pectin nasal s more
Introduction Global Markets Direct’s, 'Cancer Pain - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and disco more
Introduction GlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, H1, 2012" provides data on the Cancer Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Pain. It includes an overview of the trial n more
Introduction Global Markets Direct’s, 'Cancer Pain - Pipeline Review, H1 2012', provides an overview of the Cancer Pain therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discon more
Inflammation is a defense mechanism of the body to protect it from infection and injury. The inflammatory response is started by white blood cells releasing defense molecules to remove injurious stimuli such as damaged cells, pathogens or irritants. Redness, pain, swelling, heat and loss of more
Home About us Services Discovery Programs Technologies News&Events Careers News&Events Contact Download Privacy Disclaimer Site map 2010 News News 2010 2009 2008 2007 2006 2005 2004 2003 Events 2010 2009 2008 2007 2006 2005 2004 June 2010 Axxam and Lonza Announce the Signing of a Lic more
The Company Products & Technologies PR and Publications Career Company News HUENENBERG and ZURICH, Switzerland – September 14, 2009 Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
